Zobrazeno 1 - 10
of 37
pro vyhledávání: '"Henry L.‐Y. Chan"'
Publikováno v:
JGH Open, Vol 7, Iss 2, Pp 141-147 (2023)
Abstract Background and Aim Adenosine triphosphate (ATP) bioluminescence assay is widely adopted in the West to allow rapid evaluation of endoscopes for bacteriologic/biologic residue, but this practice is rarely adopted in Asia. In this continuous q
Externí odkaz:
https://doaj.org/article/72507493234b401493ce6192b9c6cb00
Autor:
Henry L Y Chan, Arndt Vogel, Thomas Berg, Enrico N De Toni, Masatoshi Kudo, Jörg Trojan, Anja Eiblmaier, Hanns‐Georg Klein, Johannes Kolja Hegel, Ashish Sharma, Kairat Madin, Vinzent Rolny, Marcus‐Rene Lisy, Teerha Piratvisuth
Publikováno v:
JGH Open, Vol 6, Iss 5, Pp 292-300 (2022)
Abstract Background and Aims Prothrombin induced by vitamin K absence‐II (PIVKA‐II) is a serum biomarker linked to hepatocellular carcinoma (HCC), showing superiority to alpha‐fetoprotein (AFP) for early disease detection. We aimed to assess th
Externí odkaz:
https://doaj.org/article/7e8b7a05590044d59aa5f12f135bf5f8
Autor:
Dara L Burdette, Scott Lazerwith, Jenny Yang, Henry L Y Chan, William E Delaney Iv, Simon P Fletcher, Tomas Cihlar, Becket Feierbach
Publikováno v:
PLoS ONE, Vol 17, Iss 4, p e0262516 (2022)
Nucleos(t)ide analogs are standard-of-care for the treatment of chronic hepatitis B and can effectively reduce hepatitis B virus (HBV) replication but rarely leads to cure. Nucleos(t)ide analogs do not directly eliminate the viral episome, therefore
Externí odkaz:
https://doaj.org/article/64121a6c234a4cceb57a7fd1d0b65807
Autor:
Harry L A Janssen, Jinlin Hou, Tarik Asselah, Henry L Y Chan, Fabien Zoulim, Yasuhito Tanaka, Ewa Janczewska, Ronald G Nahass, Stefan Bourgeois, Maria Buti, Pietro Lampertico, Oliver Lenz, Thierry Verbinnen, Joris Vandenbossche, Willem Talloen, Ronald Kalmeijer, Maria Beumont, Michael Biermer, Umesh Shukla
Publikováno v:
Gut. BMJ Publishing Group
Scientia
Scientia
ObjectiveWe present the final analysis results of the phase 2 JADE study (ClinicalTrials.gov Identifier:NCT03361956).Design232 patients with chronic hepatitis B (CHB) not currently treated at study start (NCT) at study start or virologically suppress
Autor:
Ondrej Podlaha, Edward Gane, Maurizia Brunetto, Scott Fung, Wan-Long Chuang, Calvin Q. Pan, Zhaoshi Jiang, Yang Liu, Neeru Bhardwaj, Prasenjit Mukherjee, John Flaherty, Anuj Gaggar, Mani Subramanian, Namiki Izumi, Shalimar, Young-Suk Lim, Patrick Marcellin, Maria Buti, Henry L. Y. Chan, Kosh Agarwal
Publikováno v:
Scientific Reports, Vol 9, Iss 1, Pp 1-9 (2019)
Abstract Despite the high global prevalence of chronic hepatitis B (CHB) infection, datasets covering the whole hepatitis B viral genome from large patient cohorts are lacking, greatly limiting our understanding of the viral genetic factors involved
Externí odkaz:
https://doaj.org/article/8a1e909a6e354d32b320dc74b869d649
Autor:
Kenneth W. Lin, Rajneesh Kumar, Feng Shen, Henry L.‐Y. Chan, Grace L.‐H. Wong, Rahul Kumar, Wan Cheng Chow, Su Lin, Vincent W.‐S. Wong, Jian‐Gao Fan, George B.‐B. Goh
Publikováno v:
Liver International. 43:1008-1014
Autor:
Thomas Tu, Harout Ajoyan, Rifqiyah nur Umami, Vaishnavi Veeraraghavan, Mustafa Ahmed M Najim, Anis Khan, Ali Bayoumi, Vikki Ho, Mohammed Eslam, Thomas Berg, Henry L Y Chan, Jacob George, Mark W Douglas
Introduction Chronic viral hepatitis, a leading cause of global deaths, is caused by three enveloped viruses from distinct families: hepatitis B virus, hepatitis C virus, and hepatitis D virus (HBV, HCV, and HDV). Despite having different replication
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::c8729d77eb174bd1f49b8c8813a66f95
https://doi.org/10.21203/rs.3.rs-2824838/v1
https://doi.org/10.21203/rs.3.rs-2824838/v1
Autor:
Man‐Fung Yuen, Chi‐Yi Chen, Chun‐Jen Liu, Wen‐Juei Jeng, Magdy Elkhashab, Carla S. Coffin, Won Kim, Susan Greenbloom, Alnoor Ramji, Young S. Lim, Yoon J. Kim, Scott K. Fung, Dong J. Kim, Jeong‐Won Jang, Kwan Sik Lee, Radhakrishnan P. Iyer, Chelsea Macfarlane, Kathy Jackson, Stephen A. Locarnini, Henry L. Y. Chan, Nezam H. Afdhal
Publikováno v:
Liver international : official journal of the International Association for the Study of the LiverREFERENCES. 43(1)
Novel agents acting against hepatitis B virus (HBV) are needed to improve HBsAg seroclearance or termed as 'functional cure'. Inarigivir (retinoic acid-inducible gene I agonist) has immunomodulatory and direct antiviral actions against HBV. We aimed
Autor:
Teerha Piratvisuth, Piyawat Komolmit, Tawesak Tanwandee, Wattana Sukeepaisarnjaroen, Henry L Y Chan, Mário G Pessôa, Eduardo Fassio, Suzane K Ono, Fernando Bessone, Jorge Daruich, Stefan Zeuzem, Hugo Cheinquer, Rashidkhan Pathan, Yuhong Dong, Aldo Trylesinski
Publikováno v:
PLoS ONE, Vol 8, Iss 2, p e54279 (2013)
The Roadmap concept is a therapeutic framework in chronic hepatitis B for the intensification of nucleoside analogue monotherapy based on early virologic response. The efficacy and safety of this approach applied to telbivudine treatment has not been
Externí odkaz:
https://doaj.org/article/80753a973561437b84b7bcea898690c2
Autor:
Jordan J, Feld, Ira M, Jacobson, Christophe, Hézode, Tarik, Asselah, Peter J, Ruane, Norbert, Gruener, Armand, Abergel, Alessandra, Mangia, Ching-Lung, Lai, Henry L Y, Chan, Francesco, Mazzotta, Christophe, Moreno, Eric, Yoshida, Stephen D, Shafran, William J, Towner, Tram T, Tran, John, McNally, Anu, Osinusi, Evguenia, Svarovskaia, Yanni, Zhu, Diana M, Brainard, John G, McHutchison, Kosh, Agarwal, Stefan, Zeuzem, Curt, Hagedorn
Publikováno v:
New England Journal of Medicine. 373:2599-2607
A simple treatment regimen that is effective in a broad range of patients who are chronically infected with the hepatitis C virus (HCV) remains an unmet medical need.We conducted a phase 3, double-blind, placebo-controlled study involving untreated a